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Abstract, ras family genes (H-, K- and N-ras) encode for a 
21 kD membrane protein which possesses GTPase activity 
and participates in a signal transduction pathway. Activating 
mutations of the ras family genes occur at codons 12, 13 and 
61 and have been detected in a variety of human tumours, 
including colonic, bladder and pancreatic cancers. Prostatic 
cancer is among the most common malignancies throughout 
the world and a major cause of death from cancer in males. 
Data reported on the implication of the ras family genes in 
the development of the disease are conflicting. The aim of 
this study was to determine the incidence of mutations at 
codon 12 of Η-ras, codon 12 of K-ras and codon 61 of N-ras 
proto-oncogenes, in a Greek population with prostatic cancer. 
Our analysis revealed that 4 out of 20 (20%) samples 
harboured a K-ras codon 12 point mutation, 1 out of 20 (5%) 
specimens contained mutations at codon 12 of the Η-ras and 1 
out of 20 (5%) at codon 61 of the N-ras, indicating a role for 
the ras genes in the development of the disease. 
Introduction 
Multistage carcinogenesis proceeds through the activation of 
proto-oncogenes and the inactivation of tumour suppressor 
genes (1). Among oncogenes, ras family genes (H-, K- and 
N-ras) have a critical role in the development of the disease. 
Activated ras genes have been detected in several human 
tumours, at various frequencies. Mutational activation 
represents the major activating mechanism for the ras family 
genes. Hot spots for mutations are codons 12, 13 and 61 (2). 
Apart from mutations, overexpression of the ras family 
genes, without any obvious genetic alteration, is often 
observed and could be a potential contributor to the initiation 
or development of the malignancy (3). 
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Mutations in at least one member of the ras family genes, 
have been detected in almost every human tumour, including 
colorectal, endometrial, pancreatic and lung carcinomas (4). 
Generally, ras mutations are considered as early events in 
carcinogenesis and have also been described in benign 
tumours and cancer predisposing diseases (5), leading to the 
proposal that they may serve as tumour markers. 
Prostatic cancer is one of the most common malignancies 
worldwide and a major cause of death from cancer in males 
in the Western world. The implication of the ras family 
genes in the development of prostatic cancer has not been 
studied in depth and the available data are still conflicting. 
Several investigators have proposed a minor role for the ras 
family genes in the development of prostatic cancer, with the 
majority of the sparse mutations, affecting mainly codon 12 
of the Η-ras gene (6-8). However, a Japanese group detected 
activating mutations at codon 12 of the K-ras gene, in 
approximately 25% of the samples tested (9). This finding 
could be interpreted as a reflection of the different 
environmental factors between the Western world and Japan, 
providing further evidence to the suggestion that ras family 
genes behave in a carcinogen specific manner. In addition, 
prostatic tumours induced by N-methyl-N-nitrosourea in rats, 
frequently develop mutations at codon 12 of K-ras gene (10). 
The aim of our study was to determine the incidence of 
point mutations of the Η-ras at codon 12, K-ras at codon 12 
and N-ras at codon 61 in adenocarcinomas of the prostate in 
Greek patients. 
Materials and methods 
Specimens. 20 formalin fixed paraffin-embedded tissue 
sections from adenocarcinomas of the prostate, were 
obtained by the Medical School, University of Thrace, 
Alexandroupolis, Greece. The clinicopathological parameters 
of the patients are given in Table I. 
DNA extraction. Paraffin sections were digested overnight at 
50°C in a solution containing 100 mM NaCl, 10 mM Tris, 25 
mM EDTA, 0.5% SDS and 100 μ§/ηι1 proteinase K, 
followed by phenol/chloroform extraction. DNA was ethanol 
precipitated. DNA from the cell lines SW480 (positive 
control for codon 12 K-ras mutation) and HL60 (positive 
control for codon 61 JM-ras mutation) was isolated in a 
similar manner. 
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Table I. Clinicopathological parameters of 20 adenocarcinomas of the prostate. 
Patients H-ras codon 12 K-ras codon 12 N-ras codon 61 Histological Stage 
number point mutation point mutation point mutation differentiation 
1 - + 
2 - -
3 - -
4 + -
5 - -
6 - -
7 - + 
8 - -
9 - -
10 
11 
12 
13 
14 
15 
16 - + 
17 
18 
19 
20 - + + 
Table II. PCR primers, PCR products and digestion products for the detection of mutations at codon 12 of H-ras, 12 of K-ras 
and codon 61 of N-ras. 
Η-ras codon 12 K-ras codon 12 N-ras codon 61 
set of primers 5'-GAGACCCTGTAGGAGGACCC-3' 5'-ACTGAATATAAACTTGTGGTA 5'-GACATACTGGATACAGCTGGC-3' 
used GTTGGACCT-3' 
5'-TCAGGGAGCAGAGTCGTGGG-3' 5'-CCAGGTCCTGGTAAGAACT-3' S'-CTGGTTATGTACTCCTGTCC-S' 
157 bp 65 bp 
normal, 113 bp normal, 44 bp 
mutant, 144 bp mutant, 65 bp 
PCR amplification. The amplification reactions, were overnight with 20 U MscI, at 37°C. Enzymes were purchased 
performed in a 50 μΐ reaction volume containing 200 ng of from New England Biolabs. 
genomic DNA, 500 μΜ dNTPs, 10 pM of each forward and Digestion products were electrophoresed through a 2% 
reverse primer (Table II), 0.5 U of Taq DNA polymerase and agarose gel for K-ras and Η-ras or an 8% native 
5 μΐ of 10X buffer (670 mM Tris HCl, pH 8.5; 166 mM Polyacrylamide gel for N-ras. Gels were stained with 
(NH 4) 3S0 4; 67 mM MnCl2; 1.7 mg/ml BSA; 100 μΜ, ß- ethidium bromide and visualised on a UV transilluminator. 
mercaptoethanol and 1% (w/v) Triton X-100). DNA was 
initially denatured for 5 min at 95°C and amplified for 35 Results and Discussion 
cycles of 95°C for 30 sec (denaturation), 58°C for 30 sec 
(annealing) and 45 sec at 72°C (extension). In the present study we analysed 20 adenocarcinomas of the 
prostate for mutations of the Η-ras, K-ras and N-ras proto-
RFLP analysis. H-ras codon 12: 10-20 μΐ of the amplification oncogenes. Tumour specimens were obtained from patients 
product were digested overnight with 20 U Mspl, at 37°C. with various stages and histological differentiation of the 
K-ras codon 12: 10-20 μΐ of the amplification product were disease. The analysis revealed the presence of 4 out of 20 
digested for 3 h with 20 U BstNI, at 60°C. N-ras codon 61: (20%) mutant samples at K-ras codon 12 (Fig. 1), 1 out of 20 
10-20 μΐ of the amplification product were digested (5%) at H-ras codon 12 (Fig. 2) and 1 out of 20 (5%) N-ras 
PCR product 
Digestion 
product 
312 bp 
normal, 236 bp 
mutant, 291 bp 
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Figure 1. Mutations at K.-ras codon 12 detected by a combined PCR-RFLP 
assay. Lanes 1 and 5: normal samples, lanes 2, 3 and 4: mutant samples, 
lane 6: DNA from the cell line SW480 harbouring only a mutant allele, lane 7: 
undigested PCR product, M; molecular weight DNA marker. 
Figure 2. Mutations in codon 61 of the N-ras gene were detected by PCR-
RFLP analysis. M: pBR322/HaeIII DNA marker. Lane 2: Undigested 
positive control (HL60 cell line) (65 bp), lane 3: positive control digested 
with MscI, lanes 4-11: PCR products digested with Mscl. Resistance to 
MscI digestion (lane 10) indicates a mutated N-ras gene in codon 61. 
codon 61 (Fig. 3). All but one of the K-ras mutant samples 
were poorly differentiated tumours (Table I), associating the 
activating mutation with low level of differentiation. The 
stage of the disease for the mutant samples has been 
classified as A for two of them and as Β and C for the rest of 
the samples, indicating no association with the aforementioned 
clinicopathological parameter. Patients with Η-ras and N-ras 
mutations (patients number 4 and 20 respectively) had well 
differentiated stage A tumours. Patient number 20 had a 
concurrent K-ras codon 12 and N-ras codon 61 point 
mutation. 
In all cases with a mutation, the normal allele has been 
retained. In models of colorectal (11) and skin carcinogenesis 
(12), the deletion of the normal allele has been proposed to 
follow the ras mutation, in a later stage of the tumour 
Figure 3. Mutations at codon 12 of H-ras detected by PCR-RFLP. Lanes 1-7: 
PCR products digested with Mspl. Resistance to Mspl digestion (lane 5) 
indicates the presence of a mutation. M; molecular weight DNA marker. 
progression. It might be argued that if the mutations in the 
ras family genes play a significant role in the development of 
prostatic cancer, as suggested by this and other studies 
(6,9,10), heterozygosity is sufficient for the development of a 
malignant change and a gene dosage effect may play a minor 
role. 
Several investigators have explored the incidence of ras 
mutations in prostatic cancer. In some cases the reported 
incidence of mutations was very low (1-10%) and almost 
exclusively restricted to the Η-ras proto-oncogene (6-8). 
Mutations in the K-ras and N-ras have rarely been detected. 
However, the forementioned results are contrary to the 
results of a Japanese group (9) which reported a relatively 
high (25%) frequency of K-ras mutations in prostatic cancer. 
This finding possibly reflects the influence of environmental 
factor(s) in Japan that specifically mutate the K-ras proto­
oncogene. Specific mutations in the K-ras proto-oncogene 
are also caused by N-methyl-N-nitrosourea (10) in rats. Such 
a behaviour is similar to that reported for ras family gene 
mutations in cancer of the head and neck. The incidence of 
mutations is very low in the Western world, while it is almost 
30% in India and it is associated with tobacco chewing (13). 
The relatively high incidence of K-ras mutations 
described in our study also suggests that some environmental 
factor(s) are responsible for the presence of these genetic 
alterations. Identification of the precise nature of the 
mutations could give us more information. 
The preference exhibited by the K-ras point mutations to 
the poorly differentiated tumours argues in favour of a role 
for the ras genes and the K-ras in particular in the 
pathogenesis of prostatic cancer. However, overexpression of 
the ras family genes should also be considered as a 
contributing factor in the development of prostatic cancer. 
This study indicates that the ras genes may have a role in 
the development and progression of prostatic cancer. A more 
detailed analysis involving a large number of patients is 
required in order to establish the precise role of the ras 
family genes in prostatic cancer. 
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